Heart Disease Clinical Trials 2024

Heart Disease Clinical Trials 2024

Heart Disease research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in heart disease clinical trials today.

Trials for Single Ventricle Heart Disease Patients

Trials for SVHD Patients

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to heart disease

What are the top hospitals conducting heart disease research?

When it comes to advancing medical knowledge and finding innovative solutions for heart disease, several hospitals are at the forefront of groundbreaking clinical trials. In Rochester, Minnesota, the Mayo Clinic leads the charge with four active trials focused on heart disease. This renowned institution has a long-standing reputation for excellence in healthcare and research. Similarly, the University of Ottawa Heart Institute in Canada is dedicated to combating heart disease through three ongoing clinical trials. Located in Ottawa's capital city, this institute brings together leading experts in cardiology who strive to improve patient outcomes.

In Edmonton, Alberta, the University of Alberta is actively contributing to our understanding and treatment of heart disease through three current clinical trials. Situated amidst Canada's stunning natural beauty, this hospital combines cutting-edge research with compassionate care. Additionally making strides in heart disease research is Banner University Medical Center in Phoenix where two ongoing clinical trials are underway. This center boasts state-of-the-art facilities and a multidisciplinary approach that ensures comprehensive patient care.

Lastly but certainly not leastly; UC Health Northern Colorado/Medical Center of the Rockies located Loveland has also committed itself towards furthering our knowledge about complications related to heart diseases by conducting two active experiments as they do their part while having no previous records regarding such undertakings before following its pledge towards pioneering efforts providing ample opportunities treating cardiovascular disorders.

These esteemed hospitals represent beacons of hope for those affected by heart disease worldwide—dedicated teams working tirelessly to find answers and develop better treatments. By participating in these innovative clinical trials, patients play an integral role in shaping future advancements that have far-reaching implications for countless lives impacted by this prevalent condition

Which are the best cities for heart disease clinical trials?

In the realm of heart disease clinical trials, several cities emerge as prominent hubs for research. New york, New York takes the lead with 10 active studies exploring a diverse range of treatments such as SAPIEN 3 THV and the utilization of a 3D model of the heart. Following closely behind are Rochester, Minnesota and Los Angeles, California, both with 6 ongoing trials investigating interventions like Edwards SAPIEN 3/SAPIEN 3 Ultra THV. Boston, Massachusetts and Chicago, Illinois also contribute to the field with their respective sets of active trials focused on advancements in heart disease management. These cities serve as invaluable centers for innovative research that holds promise for improving outcomes in individuals affected by heart disease.

Which are the top treatments for heart disease being explored in clinical trials?

Heart disease research is advancing rapidly, with several innovative treatments taking center stage in clinical trials. Leading the charge are three standout contenders:

  • Daratumumab: This powerful drug has shown great promise in six active trials for heart disease, demonstrating its potential to revolutionize treatment options.
  • Belantamab mafodotin: With four ongoing trials, belantamab mafodotin is making waves as a potential breakthrough therapy for heart disease.
  • Lenalidomide: A well-established player in the field of medicine, lenalidomide continues to shine with three active trials dedicated to exploring its efficacy against heart disease. These cutting-edge treatments offer hope for patients and signify significant progress on the path toward improved cardiac care.
What are the most recent clinical trials for heart disease?

Exciting developments in the field of heart disease research have emerged through recent clinical trials. One such trial involves CagriSema, a potential treatment for heart disease that has reached Phase 3 of testing. Additionally, researchers are exploring the efficacy and safety of a new therapeutic approach known as "Treated" in Phase 1 trials. Another study focuses on the de-adoption of beta-blockers as a treatment option for heart disease in Phase 4 investigations. Furthermore, Sulfur Hexafluoride Lipid Type A Microspheres Suspension and NNC6019-0001 show promise in their respective phases, bolstering hopes for improved management and outcomes for individuals living with heart disease.

What heart disease clinical trials were recently completed?

Several recent clinical trials focused on advancements in treating heart disease have reached completion, showcasing the commitment of researchers to improving cardiovascular health. Notably, a trial sponsored by Boston Scientific Corporation investigated the effectiveness of a novel cardiac device and concluded recently. Additionally, a study conducted by the National Heart, Lung, and Blood Institute examined the impact of an innovative medication on reducing cardiovascular risk factors and was finalized this year. These accomplished trials represent significant strides in our understanding and treatment options for heart disease patients.